Irritable Bowel Syndrome (IBS) Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Irritable Bowel Syndrome (IBS) market size was valued at USD 4874.3 million in 2022 and is forecast to a readjusted size of USD 12470 million by 2029 with a CAGR of 14.4% during review period.

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.

This report is a detailed and comprehensive analysis for global Irritable Bowel Syndrome (IBS) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Irritable Bowel Syndrome (IBS) market size and forecasts, in consumption value ($ Million), 2018-2029
Global Irritable Bowel Syndrome (IBS) market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Irritable Bowel Syndrome (IBS) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Irritable Bowel Syndrome (IBS) market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Irritable Bowel Syndrome (IBS)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Irritable Bowel Syndrome (IBS) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Bausch Health
   Allergan
   Takeda
   Sucampo Pharmaceuticals (Mallinckrodt)
   Sebela Pharmaceuticals Inc
   Astellas Pharmaceuticals

   IBS-D Drug
   IBS-C Drug
   Others
 

   Women
   Men

   North America (United States, Canada, and Mexico)
   Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
   South America (Brazil, Argentina and Rest of South America)
   Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

What are the strengths of the IBS market in 2025?

The IBS market in 2025 benefits from increasing awareness and improved diagnostic capabilities, which help early detection and better treatment options. Advancements in personalized medicine and innovative drug therapies, such as targeted therapies and gut microbiome treatments, enhance the effectiveness of treatments for patients. Additionally, strong market growth is driven by the rising prevalence of IBS globally, especially in developed countries.

What are the weaknesses in the IBS market in 2025?

A significant weakness lies in the lack of a standardized treatment approach for IBS, as its symptoms vary widely between patients. Additionally, the complexity of IBS, with multiple potential causes, leads to challenges in creating universally effective therapies. There is also a high level of patient dissatisfaction with existing treatments due to side effects or lack of efficacy, contributing to gaps in the market.

What are the opportunities for the IBS market in 2025?

There is a growing opportunity in the development of non-pharmacological treatments such as dietary interventions, probiotics, and digital health solutions. The increasing focus on gut health and the microbiome presents untapped potential for innovative therapies targeting the gut-brain axis. Moreover, the rising demand for personalized medicine and the potential for gene-based treatments offer lucrative avenues for companies to explore.

What are the threats to the IBS market in 2025?

Competitive pressure from generic drugs and alternative therapies such as herbal treatments poses a threat to the profitability of prescription medications. Additionally, the market may face regulatory hurdles, as new treatments and drugs undergo stringent testing before approval. Misdiagnosis or underdiagnosis of IBS in certain regions could also impact market growth. Lastly, economic constraints in some regions may limit access to newer, more effective treatments.

What are the political factors affecting the IBS market in 2025?

Government regulations and policies related to healthcare and drug approval play a crucial role in shaping the IBS market. Increased focus on healthcare access and insurance coverage in some regions may improve patient access to treatments. Political stability and public healthcare spending also influence the availability of treatments, particularly in developing countries.

How do economic factors impact the IBS market in 2025?

Economic factors, such as the overall economic growth in developed regions and disposable income, can affect patients' ability to afford expensive IBS treatments. Economic downturns may limit the adoption of newer therapies, while in regions with higher healthcare budgets, there is greater demand for advanced IBS treatments. Rising healthcare costs may also encourage patients to seek more affordable or alternative solutions.

What social factors are influencing the IBS market in 2025?

Social awareness of IBS and gastrointestinal health has been increasing, leading to more patients seeking treatment. Changing lifestyles, such as increased stress and poor dietary habits, contribute to a rise in IBS cases, particularly in urban areas. There is also a growing trend towards holistic and lifestyle-based management of IBS, such as dietary changes and probiotics, driven by a focus on preventive healthcare.

How does technology impact the IBS market in 2025?

Advances in technology, such as telemedicine and digital health tools, are improving patient management and providing greater access to care. Innovations in precision medicine, such as microbiome-based therapies, are opening new avenues for IBS treatment. Additionally, wearable devices and health apps are helping patients track their symptoms and manage IBS more effectively, making treatment more personalized and data-driven.

What environmental factors affect the IBS market in 2025?

Environmental factors like pollution and climate change may influence the rise of IBS, as stress and environmental pollutants can exacerbate symptoms. Moreover, awareness of sustainable and environmentally-friendly packaging for IBS-related medications is gaining importance, as consumers are becoming more conscious of ecological impacts.

What legal factors are influencing the IBS market in 2025?

Stringent regulatory requirements for drug approval and clinical trials can impact the speed at which new IBS treatments reach the market. Intellectual property laws also affect market competition, as pharmaceutical companies race to develop novel therapies. Laws surrounding patient data privacy and the use of digital health technologies are evolving, which may affect how IBS management tools and treatments are utilized.

Who are the suppliers in the IBS market in 2025?

Suppliers in the IBS market include pharmaceutical companies that produce medications, healthcare providers offering diagnostic services, and manufacturers of over-the-counter supplements like probiotics and fiber supplements. Additionally, suppliers of digital health solutions, such as telemedicine platforms and mobile apps for symptom tracking, are also key players.

What are the inputs in the IBS market in 2025?

The inputs in the IBS market involve raw materials for pharmaceutical production, research data on IBS pathophysiology, and technological advancements for diagnostics and treatment. Key inputs also include patient data, healthcare infrastructure, and investment in clinical trials to bring new treatments to market.

What is the process in the IBS market in 2025?

The process in the IBS market includes the identification of IBS symptoms, followed by diagnosis using medical testing and imaging. Treatment then proceeds with medication, dietary changes, and other therapeutic interventions like probiotics or cognitive behavioral therapy. Ongoing patient monitoring and adjustment of treatment plans are key processes for managing the condition effectively.

Who are the customers in the IBS market in 2025?

Customers in the IBS market include individual patients suffering from IBS, healthcare providers who diagnose and treat the condition, and insurance companies that may cover treatment costs. Additionally, digital health consumers seeking mobile solutions for symptom tracking and advice are emerging customers.

What are the outputs in the IBS market in 2025?

The outputs in the IBS market include improved health outcomes for patients, such as symptom relief and better quality of life. Other outputs involve the development of new therapies, clinical guidelines, and a growing body of research data on the effectiveness of various treatments. Additionally, digital tools and patient education materials are key outputs.

How strong is the threat of new entrants in the IBS market in 2025?

The threat of new entrants in the IBS market is moderate. While the market presents lucrative opportunities, high barriers to entry, such as strict regulatory approvals and the need for significant research and development, make it difficult for new players to quickly establish themselves. Established pharmaceutical companies and medical device manufacturers dominate the market, making it challenging for newcomers to compete.

How intense is the bargaining power of suppliers in the IBS market in 2025?

The bargaining power of suppliers is moderate. Pharmaceutical companies and suppliers of active ingredients hold some power, but the increasing availability of generic drugs and alternative treatment options reduces this influence. Furthermore, the rise of digital health platforms and dietary supplements adds to the diversity of suppliers, reducing the overall power of traditional pharmaceutical suppliers.

How high is the bargaining power of buyers in the IBS market in 2025?

The bargaining power of buyers is relatively high. Patients and healthcare providers have access to a wide variety of treatments, including pharmaceuticals, lifestyle interventions, and digital health solutions. As awareness about IBS grows, patients are becoming more informed and can seek out the most cost-effective and efficient treatments, increasing their bargaining power.

How strong is the threat of substitute products in the IBS market in 2025?

The threat of substitutes is high. Non-pharmaceutical treatments like probiotics, dietary adjustments, and alternative therapies, such as herbal supplements, offer substitutes for traditional IBS medications. Additionally, digital health tools, including symptom-tracking apps and telemedicine consultations, are emerging as substitutes for in-person visits and conventional treatments.

How intense is the rivalry among existing competitors in the IBS market in 2025?

The rivalry among existing competitors is high. The market is competitive, with numerous pharmaceutical companies, supplement manufacturers, and digital health platforms all vying for market share. As the demand for IBS treatments grows, companies are continuously innovating, launching new therapies, and trying to differentiate themselves through clinical efficacy, patient experience, and cost-effectiveness.

What are the key raw materials and resources for the IBS market in 2025?

The key raw materials and resources for the IBS market include active pharmaceutical ingredients (APIs) used in IBS medications, such as fiber supplements, anti-spasmodic drugs, and probiotics. Additionally, resources like advanced diagnostic tools, clinical trial data, and technological infrastructure for digital health solutions play an essential role in the development of IBS treatments and management tools.

What are the main suppliers in the IBS market in 2025?

The main suppliers include pharmaceutical companies that produce IBS-specific drugs and treatments, biotechnology firms working on innovative therapies, and companies producing dietary supplements, including probiotics, fiber, and digestive enzymes. Also, suppliers of medical devices, diagnostic tools, and digital health platforms, such as symptom-tracking apps, are significant contributors.

What technological innovations are shaping the upstream sector of the IBS market?

Technological innovations shaping the upstream sector include advances in precision medicine, gut microbiome research, and personalized treatment plans. Development of new drug delivery systems, such as extended-release medications, and the use of AI in diagnostic tools to identify IBS more accurately also play a key role in transforming upstream processes. Additionally, the rise of telemedicine and digital health platforms is influencing upstream development.

How do regulatory and policy factors affect the upstream supply chain for IBS treatments in 2025?

Regulatory and policy factors significantly impact the upstream supply chain, as strict drug approval processes and clinical trial requirements can delay the launch of new IBS treatments. Additionally, government policies regarding healthcare access, insurance coverage for IBS treatments, and patent laws for new therapies influence the availability and cost of medications and diagnostic tools in the market.

What challenges are suppliers facing in the IBS market in 2025?

Suppliers face challenges such as the high cost of research and development for new therapies, especially with IBS being a complex, multifactorial condition. There is also increasing pressure to produce cost-effective solutions, as healthcare systems face budget constraints. Moreover, regulatory hurdles and competition from generic drug manufacturers or alternative treatments like probiotics can also hinder suppliers’ ability to maintain profitability.

What are the key processes in the midstream of the IBS market in 2025?

The key processes in the midstream of the IBS market include the formulation and manufacturing of IBS-specific drugs, the development of clinical trials, and the production of diagnostic tools. Additionally, the integration of technology in patient care, such as the creation of mobile apps for symptom monitoring, and the adoption of telemedicine for consultations, play significant roles in enhancing treatment delivery.

Who are the key players in the midstream of the IBS market in 2025?

Key players in the midstream include pharmaceutical companies developing and manufacturing IBS drugs, biotechnology firms focusing on microbiome-based therapies, and diagnostic companies providing tests to accurately diagnose IBS. Moreover, technology companies providing digital health solutions and telemedicine platforms for remote monitoring and patient engagement are also central to the midstream.

What role do partnerships and collaborations play in the midstream of the IBS market in 2025?

Partnerships and collaborations are crucial in accelerating innovation and expanding access to effective treatments. Pharmaceutical companies collaborate with research institutions to develop new drugs, while tech companies partner with healthcare providers to develop integrated digital health platforms. Collaborative efforts also extend to clinical trials and regulatory approval processes, where multiple stakeholders work together to ensure successful outcomes.

How do distribution channels affect the midstream of the IBS market in 2025?

Distribution channels in the IBS market are influenced by the growing demand for both prescription medications and over-the-counter treatments. Traditional distribution channels such as pharmacies, hospitals, and clinics remain essential, but digital health solutions and e-commerce platforms are becoming increasingly important. The ability to deliver IBS management tools and treatments directly to patients through online pharmacies or health apps helps improve accessibility.

What are the challenges faced in the midstream of the IBS market in 2025?

Challenges in the midstream include the complexity of ensuring consistent production quality for IBS treatments, especially with the rise of biologics and personalized therapies. There are also regulatory hurdles to navigate, including clinical trial approvals and the introduction of new treatment protocols. Additionally, the integration of digital health technologies into traditional healthcare systems can face resistance due to concerns around data privacy and regulatory compliance.

What are the key activities in the downstream of the IBS market in 2025?

The key activities in the downstream of the IBS market involve the distribution and sale of IBS treatments, including prescription medications, over-the-counter products, and dietary supplements. Additionally, patient education and ongoing management of the condition through healthcare professionals, digital platforms, and wellness apps are critical components. Follow-up care, including symptom tracking and adjusting treatment regimens, also plays a major role.

Who are the key players in the downstream of the IBS market in 2025?

Key players in the downstream of the IBS market include healthcare providers such as gastroenterologists, primary care physicians, and dietitians who are responsible for diagnosis and treatment. Pharmacies, both physical and online, as well as e-commerce platforms selling IBS-related products, are also essential. Digital health companies offering symptom-tracking apps and telemedicine services are increasingly important in the downstream segment.

What is the role of patients in the downstream of the IBS market in 2025?

Patients play a central role in the downstream market by actively engaging in their treatment plans, which may include medication adherence, dietary adjustments, and utilizing digital health tools for symptom management. Increasing patient empowerment through access to information and personalized treatment options allows them to make informed decisions about their care, which improves overall health outcomes.

How does patient access to treatment impact the downstream of the IBS market in 2025?

Access to treatment directly affects the effectiveness of IBS management. Easier access to both prescription medications and alternative treatments through pharmacies, online platforms, and telehealth services improves patient compliance and satisfaction. The availability of cost-effective treatments and insurance coverage also ensures broader reach and adherence to prescribed therapies.

What challenges exist in the downstream of the IBS market in 2025?

Challenges in the downstream market include the variability in treatment response among patients, leading to dissatisfaction with existing therapies. There is also the issue of inconsistent patient access to quality care, particularly in rural or underserved areas. The complexity of managing a chronic condition like IBS, combined with the growing range of treatment options, can overwhelm both patients and healthcare providers. Additionally, concerns around data privacy and regulation in digital health tools can hinder widespread adoption.

Chapter 1, to describe Irritable Bowel Syndrome (IBS) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Irritable Bowel Syndrome (IBS), with revenue, gross margin and global market share of Irritable Bowel Syndrome (IBS) from 2018 to 2023.
Chapter 3, the Irritable Bowel Syndrome (IBS) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Irritable Bowel Syndrome (IBS) market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Irritable Bowel Syndrome (IBS).
Chapter 13, to describe Irritable Bowel Syndrome (IBS) research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Irritable Bowel Syndrome (IBS)
   1.2 Market Estimation Caveats and Base Year
   1.3 Classification of Irritable Bowel Syndrome (IBS) by Type
       1.3.1 Overview: Global Irritable Bowel Syndrome (IBS) Market Size by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Global Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Type in 2022
       1.3.3 IBS-D Drug
       1.3.4 IBS-C Drug
       1.3.5 Others
   1.4 Global Irritable Bowel Syndrome (IBS) Market by Application
       1.4.1 Overview: Global Irritable Bowel Syndrome (IBS) Market Size by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Women
       1.4.3 Men
   1.5 Global Irritable Bowel Syndrome (IBS) Market Size & Forecast
   1.6 Global Irritable Bowel Syndrome (IBS) Market Size and Forecast by Region
       1.6.1 Global Irritable Bowel Syndrome (IBS) Market Size by Region: 2018 VS 2022 VS 2029
       1.6.2 Global Irritable Bowel Syndrome (IBS) Market Size by Region, (2018-2029)
       1.6.3 North America Irritable Bowel Syndrome (IBS) Market Size and Prospect (2018-2029)
       1.6.4 Europe Irritable Bowel Syndrome (IBS) Market Size and Prospect (2018-2029)
       1.6.5 Asia-Pacific Irritable Bowel Syndrome (IBS) Market Size and Prospect (2018-2029)
       1.6.6 South America Irritable Bowel Syndrome (IBS) Market Size and Prospect (2018-2029)
       1.6.7 Middle East and Africa Irritable Bowel Syndrome (IBS) Market Size and Prospect (2018-2029)

2 Company Profiles

   2.1 Bausch Health
       2.1.1 Bausch Health Details
       2.1.2 Bausch Health Major Business
       2.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Product and Solutions
       2.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Bausch Health Recent Developments and Future Plans
   2.2 Allergan
       2.2.1 Allergan Details
       2.2.2 Allergan Major Business
       2.2.3 Allergan Irritable Bowel Syndrome (IBS) Product and Solutions
       2.2.4 Allergan Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Allergan Recent Developments and Future Plans
   2.3 Takeda
       2.3.1 Takeda Details
       2.3.2 Takeda Major Business
       2.3.3 Takeda Irritable Bowel Syndrome (IBS) Product and Solutions
       2.3.4 Takeda Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Takeda Recent Developments and Future Plans
   2.4 Sucampo Pharmaceuticals (Mallinckrodt)
       2.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Details
       2.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Major Business
       2.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product and Solutions
       2.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments and Future Plans
   2.5 Sebela Pharmaceuticals Inc
       2.5.1 Sebela Pharmaceuticals Inc Details
       2.5.2 Sebela Pharmaceuticals Inc Major Business
       2.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product and Solutions
       2.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Sebela Pharmaceuticals Inc Recent Developments and Future Plans
   2.6 Astellas Pharmaceuticals
       2.6.1 Astellas Pharmaceuticals Details
       2.6.2 Astellas Pharmaceuticals Major Business
       2.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product and Solutions
       2.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Astellas Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

   3.1 Global Irritable Bowel Syndrome (IBS) Revenue and Share by Players (2018-2023)
   3.2 Market Share Analysis (2022)
       3.2.1 Market Share of Irritable Bowel Syndrome (IBS) by Company Revenue
       3.2.2 Top 3 Irritable Bowel Syndrome (IBS) Players Market Share in 2022
       3.2.3 Top 6 Irritable Bowel Syndrome (IBS) Players Market Share in 2022
   3.3 Irritable Bowel Syndrome (IBS) Market: Overall Company Footprint Analysis
       3.3.1 Irritable Bowel Syndrome (IBS) Market: Region Footprint
       3.3.2 Irritable Bowel Syndrome (IBS) Market: Company Product Type Footprint
       3.3.3 Irritable Bowel Syndrome (IBS) Market: Company Product Application Footprint
   3.4 New Market Entrants and Barriers to Market Entry
   3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

   4.1 Global Irritable Bowel Syndrome (IBS) Consumption Value and Market Share by Type (2018-2023)
   4.2 Global Irritable Bowel Syndrome (IBS) Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

   5.1 Global Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Application (2018-2023)
   5.2 Global Irritable Bowel Syndrome (IBS) Market Forecast by Application (2024-2029)

6 North America

   6.1 North America Irritable Bowel Syndrome (IBS) Consumption Value by Type (2018-2029)
   6.2 North America Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2029)
   6.3 North America Irritable Bowel Syndrome (IBS) Market Size by Country
       6.3.1 North America Irritable Bowel Syndrome (IBS) Consumption Value by Country (2018-2029)
       6.3.2 United States Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       6.3.3 Canada Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       6.3.4 Mexico Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)

7 Europe

   7.1 Europe Irritable Bowel Syndrome (IBS) Consumption Value by Type (2018-2029)
   7.2 Europe Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2029)
   7.3 Europe Irritable Bowel Syndrome (IBS) Market Size by Country
       7.3.1 Europe Irritable Bowel Syndrome (IBS) Consumption Value by Country (2018-2029)
       7.3.2 Germany Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       7.3.3 France Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       7.3.4 United Kingdom Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       7.3.5 Russia Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       7.3.6 Italy Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)

8 Asia-Pacific

   8.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Type (2018-2029)
   8.2 Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2029)
   8.3 Asia-Pacific Irritable Bowel Syndrome (IBS) Market Size by Region
       8.3.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Region (2018-2029)
       8.3.2 China Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       8.3.3 Japan Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       8.3.4 South Korea Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       8.3.5 India Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       8.3.6 Southeast Asia Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       8.3.7 Australia Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)

9 South America

   9.1 South America Irritable Bowel Syndrome (IBS) Consumption Value by Type (2018-2029)
   9.2 South America Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2029)
   9.3 South America Irritable Bowel Syndrome (IBS) Market Size by Country
       9.3.1 South America Irritable Bowel Syndrome (IBS) Consumption Value by Country (2018-2029)
       9.3.2 Brazil Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       9.3.3 Argentina Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)

10 Middle East & Africa

   10.1 Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Type (2018-2029)
   10.2 Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2029)
   10.3 Middle East & Africa Irritable Bowel Syndrome (IBS) Market Size by Country
       10.3.1 Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Country (2018-2029)
       10.3.2 Turkey Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       10.3.3 Saudi Arabia Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)
       10.3.4 UAE Irritable Bowel Syndrome (IBS) Market Size and Forecast (2018-2029)

11 Market Dynamics

   11.1 Irritable Bowel Syndrome (IBS) Market Drivers
   11.2 Irritable Bowel Syndrome (IBS) Market Restraints
   11.3 Irritable Bowel Syndrome (IBS) Trends Analysis
   11.4 Porters Five Forces Analysis
       11.4.1 Threat of New Entrants
       11.4.2 Bargaining Power of Suppliers
       11.4.3 Bargaining Power of Buyers
       11.4.4 Threat of Substitutes
       11.4.5 Competitive Rivalry
   11.5 Influence of COVID-19 and Russia-Ukraine War
       11.5.1 Influence of COVID-19
       11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

   12.1 Irritable Bowel Syndrome (IBS) Industry Chain
   12.2 Irritable Bowel Syndrome (IBS) Upstream Analysis
   12.3 Irritable Bowel Syndrome (IBS) Midstream Analysis
   12.4 Irritable Bowel Syndrome (IBS) Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

   14.1 Methodology
   14.2 Research Process and Data Source
   14.3 Disclaimer

List of Tables

   Table 1. Global Irritable Bowel Syndrome (IBS) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Irritable Bowel Syndrome (IBS) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Global Irritable Bowel Syndrome (IBS) Consumption Value by Region (2018-2023) & (USD Million)
   Table 4. Global Irritable Bowel Syndrome (IBS) Consumption Value by Region (2024-2029) & (USD Million)
   Table 5. Bausch Health Company Information, Head Office, and Major Competitors
   Table 6. Bausch Health Major Business
   Table 7. Bausch Health Irritable Bowel Syndrome (IBS) Product and Solutions
   Table 8. Bausch Health Irritable Bowel Syndrome (IBS) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 9. Bausch Health Recent Developments and Future Plans
   Table 10. Allergan Company Information, Head Office, and Major Competitors
   Table 11. Allergan Major Business
   Table 12. Allergan Irritable Bowel Syndrome (IBS) Product and Solutions
   Table 13. Allergan Irritable Bowel Syndrome (IBS) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 14. Allergan Recent Developments and Future Plans
   Table 15. Takeda Company Information, Head Office, and Major Competitors
   Table 16. Takeda Major Business
   Table 17. Takeda Irritable Bowel Syndrome (IBS) Product and Solutions
   Table 18. Takeda Irritable Bowel Syndrome (IBS) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 19. Takeda Recent Developments and Future Plans
   Table 20. Sucampo Pharmaceuticals (Mallinckrodt) Company Information, Head Office, and Major Competitors
   Table 21. Sucampo Pharmaceuticals (Mallinckrodt) Major Business
   Table 22. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product and Solutions
   Table 23. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 24. Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments and Future Plans
   Table 25. Sebela Pharmaceuticals Inc Company Information, Head Office, and Major Competitors
   Table 26. Sebela Pharmaceuticals Inc Major Business
   Table 27. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product and Solutions
   Table 28. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 29. Sebela Pharmaceuticals Inc Recent Developments and Future Plans
   Table 30. Astellas Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 31. Astellas Pharmaceuticals Major Business
   Table 32. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product and Solutions
   Table 33. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 34. Astellas Pharmaceuticals Recent Developments and Future Plans
   Table 35. Global Irritable Bowel Syndrome (IBS) Revenue (USD Million) by Players (2018-2023)
   Table 36. Global Irritable Bowel Syndrome (IBS) Revenue Share by Players (2018-2023)
   Table 37. Breakdown of Irritable Bowel Syndrome (IBS) by Company Type (Tier 1, Tier 2, and Tier 3)
   Table 38. Market Position of Players in Irritable Bowel Syndrome (IBS), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
   Table 39. Head Office of Key Irritable Bowel Syndrome (IBS) Players
   Table 40. Irritable Bowel Syndrome (IBS) Market: Company Product Type Footprint
   Table 41. Irritable Bowel Syndrome (IBS) Market: Company Product Application Footprint
   Table 42. Irritable Bowel Syndrome (IBS) New Market Entrants and Barriers to Market Entry
   Table 43. Irritable Bowel Syndrome (IBS) Mergers, Acquisition, Agreements, and Collaborations
   Table 44. Global Irritable Bowel Syndrome (IBS) Consumption Value (USD Million) by Type (2018-2023)
   Table 45. Global Irritable Bowel Syndrome (IBS) Consumption Value Share by Type (2018-2023)
   Table 46. Global Irritable Bowel Syndrome (IBS) Consumption Value Forecast by Type (2024-2029)
   Table 47. Global Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2023)
   Table 48. Global Irritable Bowel Syndrome (IBS) Consumption Value Forecast by Application (2024-2029)
   Table 49. North America Irritable Bowel Syndrome (IBS) Consumption Value by Type (2018-2023) & (USD Million)
   Table 50. North America Irritable Bowel Syndrome (IBS) Consumption Value by Type (2024-2029) & (USD Million)
   Table 51. North America Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2023) & (USD Million)
   Table 52. North America Irritable Bowel Syndrome (IBS) Consumption Value by Application (2024-2029) & (USD Million)
   Table 53. North America Irritable Bowel Syndrome (IBS) Consumption Value by Country (2018-2023) & (USD Million)
   Table 54. North America Irritable Bowel Syndrome (IBS) Consumption Value by Country (2024-2029) & (USD Million)
   Table 55. Europe Irritable Bowel Syndrome (IBS) Consumption Value by Type (2018-2023) & (USD Million)
   Table 56. Europe Irritable Bowel Syndrome (IBS) Consumption Value by Type (2024-2029) & (USD Million)
   Table 57. Europe Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2023) & (USD Million)
   Table 58. Europe Irritable Bowel Syndrome (IBS) Consumption Value by Application (2024-2029) & (USD Million)
   Table 59. Europe Irritable Bowel Syndrome (IBS) Consumption Value by Country (2018-2023) & (USD Million)
   Table 60. Europe Irritable Bowel Syndrome (IBS) Consumption Value by Country (2024-2029) & (USD Million)
   Table 61. Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Type (2018-2023) & (USD Million)
   Table 62. Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Type (2024-2029) & (USD Million)
   Table 63. Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2023) & (USD Million)
   Table 64. Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Application (2024-2029) & (USD Million)
   Table 65. Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Region (2018-2023) & (USD Million)
   Table 66. Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Region (2024-2029) & (USD Million)
   Table 67. South America Irritable Bowel Syndrome (IBS) Consumption Value by Type (2018-2023) & (USD Million)
   Table 68. South America Irritable Bowel Syndrome (IBS) Consumption Value by Type (2024-2029) & (USD Million)
   Table 69. South America Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2023) & (USD Million)
   Table 70. South America Irritable Bowel Syndrome (IBS) Consumption Value by Application (2024-2029) & (USD Million)
   Table 71. South America Irritable Bowel Syndrome (IBS) Consumption Value by Country (2018-2023) & (USD Million)
   Table 72. South America Irritable Bowel Syndrome (IBS) Consumption Value by Country (2024-2029) & (USD Million)
   Table 73. Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Type (2018-2023) & (USD Million)
   Table 74. Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Type (2024-2029) & (USD Million)
   Table 75. Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Application (2018-2023) & (USD Million)
   Table 76. Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Application (2024-2029) & (USD Million)
   Table 77. Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Country (2018-2023) & (USD Million)
   Table 78. Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Country (2024-2029) & (USD Million)
   Table 79. Irritable Bowel Syndrome (IBS) Raw Material
   Table 80. Key Suppliers of Irritable Bowel Syndrome (IBS) Raw Materials

List of Figures

   Figure 1. Irritable Bowel Syndrome (IBS) Picture
   Figure 2. Global Irritable Bowel Syndrome (IBS) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Type in 2022
   Figure 4. IBS-D Drug
   Figure 5. IBS-C Drug
   Figure 6. Others
   Figure 7. Global Irritable Bowel Syndrome (IBS) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 8. Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Application in 2022
   Figure 9. Women Picture
   Figure 10. Men Picture
   Figure 11. Global Irritable Bowel Syndrome (IBS) Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 12. Global Irritable Bowel Syndrome (IBS) Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 13. Global Market Irritable Bowel Syndrome (IBS) Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
   Figure 14. Global Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Region (2018-2029)
   Figure 15. Global Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Region in 2022
   Figure 16. North America Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 17. Europe Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 18. Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 19. South America Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 20. Middle East and Africa Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 21. Global Irritable Bowel Syndrome (IBS) Revenue Share by Players in 2022
   Figure 22. Irritable Bowel Syndrome (IBS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
   Figure 23. Global Top 3 Players Irritable Bowel Syndrome (IBS) Market Share in 2022
   Figure 24. Global Top 6 Players Irritable Bowel Syndrome (IBS) Market Share in 2022
   Figure 25. Global Irritable Bowel Syndrome (IBS) Consumption Value Share by Type (2018-2023)
   Figure 26. Global Irritable Bowel Syndrome (IBS) Market Share Forecast by Type (2024-2029)
   Figure 27. Global Irritable Bowel Syndrome (IBS) Consumption Value Share by Application (2018-2023)
   Figure 28. Global Irritable Bowel Syndrome (IBS) Market Share Forecast by Application (2024-2029)
   Figure 29. North America Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Type (2018-2029)
   Figure 30. North America Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Application (2018-2029)
   Figure 31. North America Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Country (2018-2029)
   Figure 32. United States Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 33. Canada Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 34. Mexico Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 35. Europe Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Type (2018-2029)
   Figure 36. Europe Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Application (2018-2029)
   Figure 37. Europe Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Country (2018-2029)
   Figure 38. Germany Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 39. France Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 40. United Kingdom Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 41. Russia Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 42. Italy Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 43. Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Type (2018-2029)
   Figure 44. Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Application (2018-2029)
   Figure 45. Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Region (2018-2029)
   Figure 46. China Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 47. Japan Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 48. South Korea Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 49. India Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 50. Southeast Asia Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 51. Australia Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 52. South America Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Type (2018-2029)
   Figure 53. South America Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Application (2018-2029)
   Figure 54. South America Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Country (2018-2029)
   Figure 55. Brazil Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 56. Argentina Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 57. Middle East and Africa Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Type (2018-2029)
   Figure 58. Middle East and Africa Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Application (2018-2029)
   Figure 59. Middle East and Africa Irritable Bowel Syndrome (IBS) Consumption Value Market Share by Country (2018-2029)
   Figure 60. Turkey Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 61. Saudi Arabia Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 62. UAE Irritable Bowel Syndrome (IBS) Consumption Value (2018-2029) & (USD Million)
   Figure 63. Irritable Bowel Syndrome (IBS) Market Drivers
   Figure 64. Irritable Bowel Syndrome (IBS) Market Restraints
   Figure 65. Irritable Bowel Syndrome (IBS) Market Trends
   Figure 66. Porters Five Forces Analysis
   Figure 67. Manufacturing Cost Structure Analysis of Irritable Bowel Syndrome (IBS) in 2022
   Figure 68. Manufacturing Process Analysis of Irritable Bowel Syndrome (IBS)
   Figure 69. Irritable Bowel Syndrome (IBS) Industrial Chain
   Figure 70. Methodology
   Figure 71. Research Process and Data Source